Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Coeur Commences Drilling at Silver North's Tim Project (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

IMV Inc IMVIF

Healthcare Biotechnology
IMV Inc. is a Canada-based company. The Company has no business operations.


GREY:IMVIF - Post by User

IMV Inc > Presentations
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(2)
•••
Comment by Breakthoroughon Apr 15, 2022 8:35am
226 Views
Post# 34606164

RE:RE:RE:RE:RE:Presentations

RE:RE:RE:RE:RE:Presentations Following the data published yesterday at IMV's site, there were just 13 evaluable patients, witj 3 SD, 3 PR and 2 CR.. So it gives, as an orientation (though the cohort is very small): DCR: Intention to Treat, 47% (8 out of 17); Evaluable population, 615% (8 out of 13). ORR: ITT, 294% (5 out of 17); EVp, 385% (5 out of 13).
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities